A safety trial of trifluridine/tipiracil for DPD-deficient patients
Treatments studied
Part of Cancer, Digestive system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced colorectal or gastroesophageal cancer that has spread to other parts of your body.
- You have not received any previous treatment for your metastatic cancer.
- You have a known DPD deficiency, which means a blood test showed a high level of a substance called uracil.
- You are at least 18 years old and in generally good health (able to care for yourself).
- Your kidney and liver function are within acceptable limits based on recent blood tests.
- You agree to use effective birth control during the study and for 7 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—bevacizumab and trifluridine/tipiracil—given together to see if it lowers the risk of a serious drop in white blood cells (neutropenia) in people with advanced colorectal cancer. The goal is to make treatment safer and more tolerable.
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
This study tests a combination of two drugs, trifluridine and tipiracil, for people whose colorectal cancer has spread to other parts of the body. The goal is to see how well this treatment works in real life and if it can help you live longer or feel better.
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
This trial tests two different drug combinations for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if one combination works as well as the other, potentially offering a new option.
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.